• For Individuals
  • For Institutions
  • Download
  • Help

  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文（廣東話）Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials

Event Tracking

Jun18
Cyclo Therapeutics Advances NPC1 Phase III Clinical Trial
11:01
Jun11
Cyclo Therapeutics Completes Phase III Clinical Trial Recruitment for NPC Type C1
11:22
Apr24
Cyclo Therapeutics Completes Rare Genetic Disease Clinical Trial Recruitment
20:37
Nov15
Cyclo Therapeutics released FY2024 Q3 earnings on November 14 (EST), actual revenue 233.77 K USD (forecast 294 K USD), actual EPS -0.3074 USD (forecast -0.1566 USD)
04:00
Cyclo Therapeutics released FY2024 Cumulative 3Q Earnings on November 14 (EST), Revenue: 559.33K USD, EPS: -0.6693
04:00
Sep5
Cyclo Therapeutics Releases Preliminary Safety Data for Niemann-Pick Disease Type C1 Treatment
14:29

Schedules & Filings

Schedules
Filings
Nov14
Earning Release(EST)

FY2024 Q3 Earning Release (USD) Revenue 233.77 K, Net Income -8.833 M, EPS -0.3074

Aug14
Earning Release(EST)

FY2024 Q2 Earning Release (USD) Revenue 123.1 K, Net Income -5.981 M, EPS -0.2099

May15
Earning Release(EST)

FY2024 Q1 Earning Release (USD) Revenue 202.45 K, Net Income -4.343 M, EPS -0.1519

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
WSHP
200.000
+506.06%
+167.000
SGBX
6.070
+78.01%
+2.660
BACCR
0.3900
+77.27%
+0.170
SEMR
11.760
+73.96%
+5.000
PGACR
0.3500
+59.02%
+0.130
NUVB
7.150
+48.96%
+2.350
SSEAR
0.2999
+42.81%
+0.090
HXHX
0.7879
+41.15%
+0.230
CABR
1.090
+39.96%
+0.311
STEC
1.050
+38.82%
+0.294
View More
Terms & Conditions
  • Terms of Service
  • Privacy Policy